BioViotica

Telithromycin

Name: Telithromycin
Brand: BioViotica
SKU: BVT-0456
Price: 50.00 CHF
Availability: InStock

As low as CHF 50.00

In stock

Only %1 left

BVT-0456-M0011 mgCHF 50.00

BVT-0456-M01010 mgCHF 170.00

Specifications / Handling

More Information
Product Details
Synonyms	RU 66647; Ketek; HMR 3647
Product Type	Chemical
Properties
Formula	C₄₃H₆₅N₅O₁₀
MW	812.0
CAS	191114-48-4
RTECS	HB7878000
Source/Host Chemicals	Semi-synthetic.
Purity Chemicals	≥98% (NMR, TLC)
Appearance	White solid.
Solubility	Soluble in DMSO, ethanol, methanol, acetone or methylene chloride. Sparingly soluble in water (0.3mg/ml).
Identity	Determined by ¹H-NMR.
Declaration	Manufactured by BioViotica.
InChi Key	LJVAJPDWBABPEJ-XLSPMWLOSA-N
Smiles	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)CC([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)C2N(CCCCN3C=NC(=C3)C3=CN=CC=C3)C(=O)O[C@]12C)OC
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	+4°C
Handling Advice	Protect from light when in solution.
Use/Stability	Stable for at least 1 year after receipt when stored at +4°C.
Documents
Safety Data Sheet	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Scientific Background Information

Product Description

Ketolide type macrolide antibiotic.
Antibacterial compound used to treat mild to moderate respiratory infections.
Protein synthesis inhibitor, by binding to the 50S ribosomal subunit and subsequently blocking the progression of the growing polypeptide chain. Binds to domains II and V of the 23S rRNA of the 50S ribosomal subunit.
Has a higher affinity for these ribosomal targets than conventional macrolides due to the additional interactions and increased binding at domain II. Retains activity against Gram-positive cocci in the presence of resistance mediated by methylases (erm genes) that alter the binding site at domain V.
May inhibit the formation of ribosomal subunits 50S and 30S.

Product-specific References

The ketolide antibiotics HMR-3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection: F.G. Araujo, et al.; Antimicrob. Agents Chemother. 41, 2137 (1997)
The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent: F.J. Boswell, et al.; J. Antimicrob. Chemother. 42, 703 (1998)
Drugs of the 21st century: telithromycin (HMR 3647) - the first ketolide: G. Ackermann & A.C. Rodloff; J. Antimicrob. Chemother. 51, 497 (2003)
Telithromycin: K. Wellington & S. Noble; Drugs 64, 1683 (2004)
Telithromycin: A ketolide antibiotic for treatment of respiratory tract infections: J.R. Lonks & D.A. Goldmann; Clin. Inf. Dis. 40, 1657 (2005)
Antibacterial drug discovery-Then, now and the genomics future: R. Monaghan & J.F. Barrett; Biochem. Pharmacol. 71, 901 (2006)
Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review: C.M. Fogarty, et al.; Int. J. Infect. Dis. 10, 136 (2006)
Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia: S.D. Brown; Drug Safety 31, 561 (2008)
Time-dependent effects of Klebsiella pneumonia endotoxin on the telithromycin pharmacokinetics in rats; restoration of the parameters in 96-hour KPLPS rats to the control levels: J.H. Lee, et al.; Pulm. Pharmacol. Ther. 21, 860 (2008)
Ketolides - the modern relatives of macrolides: the pharmacokinetic perspective: M. Zeitlinger, et al.; Clin. Pharmacokinet. 48, 23 (2009)
Inducible expression of erm(B) by the ketolides telithromycin and cethromycin: P. Byoungduck & M. Yu-Hong; Int. J. Antimicrob. Agents 46, 226 (2015)
ClpP-independent function of ClpX interferes with telithromycin resistance conferred by msr(A) in Staphylococcus aureus: V. Vimberg, et al.; Antimicrob. Agents Chemother. 59, 3611 (2015)

Call	+41 61 926 6040
Fax	+41 61 926 6049